Supplementary Materials:

Materials and methods
Participants and samples
Our analysis encompasses two sub-cohorts recruited consecutively; sub-cohort 1 (74 samples) including young and older individuals, and sub-cohort 2 (168 samples) including older individuals only.
Exclusion criteria were as follows; known immunodeficiency (including HIVinfection), organ transplantation, use of immunosuppressive or immune-modulating drugs within the last year (excluding acetylsalicylic acid ≤ 100mg/day), cancer or treatment for cancer within the previous 5 years, insulin dependent diabetes, moderate or advanced renal failure, liver disease, endocrine disorders (except corrected thyroid dysfunction), manifest autoimmune disease, dementia/mental incompetence, alcohol/other drug abuse, acute infection or illness in the last 4 weeks, raised body temperature (>37.5°C), moderate or severe heart failure (NYHA III or IV), inability to lie flat. Inclusion and exclusion criteria were checked and medications recorded at the time of recruitment. A more detailed medical history was available for sub-cohort 2 only. Demographics and medications for both sub-cohorts are listed in supplementary Table S1 , relevant medical history items for sub-cohort 2 are shown in supplementary Table S2 . Venous blood (approximately 30 ml) was collected into sodium-heparin plasma tubes (BD, Oxford, UK).
Whole blood antibody staining for enumerating CD28 null CD4 T-cells
Fresh, sodium-heparin-anticoagulated whole blood (100 μL) was incubated with monoclonal, fluorescence-labeled staining antibodies as follows. Sub-cohort 1 (74 samples); CD45-APC, CD3-Violet(V)500 (BD), CD4-PB, CD8-APC-H7, CD27-PE (all BD), and CD28 AF700 (BD). Sub-cohort 2; anti-CD45-AlexaFluor(AF)700, anti-CD3- 
CMV-peptides
Twenty-five μg per peptide (PepMix TM , JPT Peptide Technologies, Berlin, Germany), each covering one complete protein, were dissolved in 100 μL of DMSO (SigmaAldrich) (0.25 μg/μL). Two μL of the 0.25 μg/μL CMV-peptide solutions were used in T-cell stimulation assays (details further down) to provide a final concentration of 1 μg/mL for each peptide. Peptides pools for the following CMV proteins were used (in n = number of individuals); UL85 (pp65) (n = 3), UL86 (n = 2), UL55 (n = 1) and UL86 / UL55 (n = 1). SEB (Sigma) dissolved in DMSO was used at 1 μg/ml (final concentration, positive control), 2 μL DMSO alone (i.e. the peptide solvent) was used as negative control.
CMV-reactivity of CD28 null CD4 T-cells
CMV-specific CD4 T-cells from 7 older CMV+ individuals were activated by incubating PBMC overnight (37°C, humidifed 5% CO2 atmosphere) with overlapping Finally, cells were washed again with PBS and re-fixed in a 0.5% paraformaldehyde (in water) and stored until analysis at 4°C in the dark.
Quality control for flow-cytometry
Comparable day-to-day performance of the LSR II was ascertained by running CS&T calibration beads (BD) on a daily basis. In addition, 8-peak Rainbow beads were used prior to every run in order to adjust PMTs in such a way that with respect to each detector, every peak was always in the same channel. 
HLA-typing and sequence analysis
Statistical Analysis
Histograms and Q/Q plots were used to determine data distribution for cell populations of interest. The Kolmogorov-Smirnov and Shapiro-Wilk tests were used to test for normality.
Non-parametric tests (Mann-Whitney) were used to compare groups. T-cell frequencies were log-transformed where appropriate for normalizing distribution or improving data presentation. P-values ≤0.05 were considered significant for single endpoints. Multiple end-point correction (Bonferroni) was applied when appropriate (p ≤0.05/n, where n is the number of endpoints).
Receiver-Operator characteristic (ROC) analysis was used in order to test the ability of parameters to discriminate groups, usually CMV-and CMV+ individuals. In the entire study cohort (n=242), hierarchical multiple linear and binary logistic regression models were generated in order to test the effect of sex, age, CMV status or the presence/absence of HLA-allele groups on the frequencies (multiple linear regression) of CD28 null CD4 T-cells or the presence or absence of an expansion (binary logistic regression). Sex was always introduced at the 1st level (block 1) of hierarchical regression models; age at the 2nd level (block 2), and CMV infection status at the 3rd level (block 3). Variable selection for HLA allele groups (linear regression) was based on a Spearman Rho correlation matrix. Alleles/allele groups correlating with another allele/allele group with R>0.3 were included but those correlating with R>0.8 were 5 excluded. Additional data reduction was achieved by principle component analysis (SPSS). Differences in regards to the frequencies of individual amino acids at certain positions in exon 2 of DRB1 or DQB1 between individuals with or without expanded CD28null CD4 T-cell populations were tested using Pearson's CHI square test. Fig. S1 . Gating strategy for the analysis of CD28 null CD4 and CD28 null CD8 T cells. (A) A Leucocyte gate was created in a CD45/SSC plot and subsequently lymphocytes were gated in a SSC/FSC plot. Singlets were gated in a FSC-A/FSC-H plot, doublets were excluded. (B) From this gate two CD3 T-cell gates were created in CD3/CD4 and CD3/CD8 fluorescence dot-plots respectively, allowing to include activated T-cells downregulating CD3, CD4, or CD8 on the surface. The two CD3 T-cell gates were then combined logically ('OR') generating the CD3 T-cell gate from which CD4 T-cells were then selected (C). For the analysis of CD28 null CD8 T-cells, CD8 T-cells were subsequently visualized in a CD27/CD28 fluorescence dot-plot to allow determining the size of the CD28 null CD8 T-cell populations (dot line) and its CD27+ and CD27 − subsets. (D) For the analysis of CD28 null CD4 T-cells, CD4 T-cells were subsequently visualized in a CD27/CD28 fluorescence dot-plot to allow determining the size of the CD28 null CD4 T-cell populations (dot line) and its CD27+ and CD27 − subsets. Arrows indicate CD28 null CD8 and CD28 null CD4 T cells. Representative plots from a CMV+ individual are shown.
Supplementary Figures
Fig. S2. Gating strategy for enumerating and phenotyping CMV-activated CD4 Tcells. (A)
A T-cell gate was created in analogy to the gating strategy shown in Supplementary  Fig S1. 
